美国 · SEC FORM 4
Personalis, Inc.
PSNL · Nasdaq · CIK 0001527753 · Healthcare · Diagnostics & Research
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
30 同一窗口内观察到的 Form 4 交易行
13 sales · 17 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2025-12-22 · Tempus AI, Inc. · $250.0K
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出中等
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Tachibana AaronCFO AND COO
○▼○▼○▼○▼▼
Hall Christopher MChief Executive Officer
○▼○▼○▼○▼▼
Chen RichardPresident and CMO
○▼▼
EASTHAM KARINDirector
○○
BOWMAN A BLAINEDirector
○
WIDDER KENNETH JDirector
○
● 买入▼ 卖出○ 其他
Showing the six most active owners; 4 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-12-22 · Tempus AI, Inc..
近期 Form 4 活动
12买入
16卖出
23其他 Form 4 交易行
27SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出13 sale line(s) · 仅供背景
其他17 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 8,427,731
- 上期报告
- 8,266,193
- 日均成交量
- 1,947,012
- 回补天数
- 4.3
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-12-22 | Tempus AI, Inc. | 买入 (P) | Common Stock | 28,000 | USD 8.93 | USD 250,040 | SEC 申报 ↗ |
| 2025-12-19 | Tempus AI, Inc. | 买入 (P) | Common Stock | 29,641 | USD 8.39 | USD 248,688 | SEC 申报 ↗ |
| 2025-12-18 | Tempus AI, Inc. | 买入 (P) | Common Stock | 31,430 | USD 7.91 | USD 248,611 | SEC 申报 ↗ |
| 2025-12-17 | Tempus AI, Inc. | 买入 (P) | Common Stock | 31,650 | USD 7.86 | USD 248,769 | SEC 申报 ↗ |
| 2025-11-25 | Tempus AI, Inc. | 买入 (P) | Common Stock | 23,600 | USD 10.62 | USD 250,665 | SEC 申报 ↗ |
| 2025-11-24 | Tempus AI, Inc. | 买入 (P) | Common Stock | 25,225 | USD 9.87 | USD 248,971 | SEC 申报 ↗ |
| 2025-11-21 | Tempus AI, Inc. | 买入 (P) | Common Stock | 26,499 | USD 9.40 | USD 249,190 | SEC 申报 ↗ |
| 2025-11-20 | Tempus AI, Inc. | 买入 (P) | Common Stock | 28,827 | USD 8.63 | USD 248,777 | SEC 申报 ↗ |
| 2025-11-19 | Tempus AI, Inc. | 买入 (P) | Common Stock | 30,645 | USD 8.12 | USD 248,837 | SEC 申报 ↗ |
| 2025-11-18 | Tempus AI, Inc. | 买入 (P) | Common Stock | 64,750 | USD 7.67 | USD 496,632 | SEC 申报 ↗ |
| 2024-08-16 | Tempus AI, Inc. | 买入 (P) | Common Stock | 3,500,000 | USD 5.07 | USD 17,745,000 | SEC 申报 ↗ |
| 2024-03-01 | MYERS WOODROW A JR | 买入 (P) | Common Stock | 10,000 | USD 1.67 | USD 16,700 | SEC 申报 ↗ |
| 2022-03-03 | Eggers Barry; Janmohamed Arif; Lightspeed General Partner Select IV, L.P.; Lightspeed Ultimate General Partner Select IV, L.L.C.; Lightspeed Venture Partners Select IV, L.P.; Mhatre Ravi; Nieh Peter | 买入 (P) | Common Stock | 265,761 | USD 9.84 | USD 2,615,043 | SEC 申报 ↗ |
| 2022-03-02 | Eggers Barry; Janmohamed Arif; Lightspeed General Partner Select IV, L.P.; Lightspeed Ultimate General Partner Select IV, L.L.C.; Lightspeed Venture Partners Select IV, L.P.; Mhatre Ravi; Nieh Peter | 买入 (P) | Common Stock | 48,989 | USD 9.96 | USD 487,930 | SEC 申报 ↗ |
| 2020-08-14 | Janmohamed Arif; Liew Jeremy; Lightspeed General Partner Select IV, L.P.; Lightspeed Ultimate General Partner Select IV, L.L.C.; Lightspeed Venture Partners Select IV, L.P.; Mhatre Ravi | 买入 (P) | Common Stock | 1,315,789 | USD 19.00 | USD 24,999,991 | SEC 申报 ↗ |
Form 4 申报证据
51 transaction lines in the latest 365-day window; 278 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-18 | Tachibana Aaron | 卖出 (S) | Common Stock | 2,931 | USD 16.22 | USD 47,541 | SEC 申报 ↗ |
| 2026-09-18 | Moore Stephen Michael | 卖出 (S) | Common Stock | 2,068 | USD 16.22 | USD 33,543 | SEC 申报 ↗ |
| 2026-09-18 | Hall Christopher M | 卖出 (S) | Common Stock | 7,459 | USD 16.22 | USD 120,985 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-18 | Tachibana Aaron | 卖出 (S) | Common Stock | 2,931 | USD 16.22 | USD 47,541 | SEC 申报 ↗ |
| 2026-09-18 | Moore Stephen Michael | 卖出 (S) | Common Stock | 2,068 | USD 16.22 | USD 33,543 | SEC 申报 ↗ |
| 2026-09-18 | Hall Christopher M | 卖出 (S) | Common Stock | 7,459 | USD 16.22 | USD 120,985 | SEC 申报 ↗ |
| 2026-09-18 | Chen Richard | 卖出 (S) | Common Stock | 3,998 | USD 16.22 | USD 64,848 | SEC 申报 ↗ |
| 2026-07-15 | Chen Richard | 卖出 (S) | Common Stock | 100,000 | USD 15.15 | USD 1,515,000 | SEC 申报 ↗ |
| 2026-07-15 | Chen Richard | 期权行权／转换 (M) | Common Stock | 100,000 | USD 2.44 | USD 244,000 | SEC 申报 ↗ |
| 2026-07-09 | Hall Christopher M | 卖出 (S) | Common Stock | 100,000 | USD 15.08 | USD 1,508,000 | SEC 申报 ↗ |
| 2026-07-09 | Hall Christopher M | 期权行权／转换 (M) | Common Stock | 100,000 | USD 1.61 | USD 161,000 | SEC 申报 ↗ |
| 2026-06-29 | Tachibana Aaron | 卖出 (S) | Common Stock | 4,982 | USD 14.00 | USD 69,748 | SEC 申报 ↗ |
| 2026-06-29 | Tachibana Aaron | 期权行权／转换 (M) | Common Stock | 4,982 | USD 5.32 | USD 26,504 | SEC 申报 ↗ |
| 2026-06-26 | Tachibana Aaron | 卖出 (S) | Common Stock | 51,251 | USD 13.18 | USD 675,488 | SEC 申报 ↗ |
| 2026-06-26 | Tachibana Aaron | 期权行权／转换 (M) | Common Stock | 51,251 | USD 7.48 | USD 383,370 | SEC 申报 ↗ |
| 2026-06-26 | Hall Christopher M | 卖出 (S) | Common Stock | 100,000 | USD 13.15 | USD 1,315,000 | SEC 申报 ↗ |
| 2026-06-26 | Hall Christopher M | 期权行权／转换 (M) | Common Stock | 100,000 | USD 1.61 | USD 161,000 | SEC 申报 ↗ |
| 2026-06-04 | Tachibana Aaron | 卖出 (S) | Common Stock | 40,000 | USD 12.01 | USD 480,400 | SEC 申报 ↗ |
| 2026-06-04 | Tachibana Aaron | 期权行权／转换 (M) | Common Stock | 40,000 | USD 9.16 | USD 366,400 | SEC 申报 ↗ |
| 2026-05-29 | Tachibana Aaron | 卖出 (S) | Common Stock | 38,799 | USD 11.58 | USD 449,292 | SEC 申报 ↗ |
| 2026-05-29 | Tachibana Aaron | 期权行权／转换 (M) | Common Stock | 38,799 | USD 9.16 | USD 355,399 | SEC 申报 ↗ |
| 2026-05-29 | Hall Christopher M | 卖出 (S) | Common Stock | 80,091 | USD 11.02 | USD 882,603 | SEC 申报 ↗ |
| 2026-05-29 | Hall Christopher M | 期权行权／转换 (M) | Common Stock | 80,091 | USD 1.61 | USD 128,947 | SEC 申报 ↗ |
| 2026-05-28 | Hall Christopher M | 卖出 (S) | Common Stock | 19,909 | USD 11.02 | USD 219,397 | SEC 申报 ↗ |
| 2026-05-28 | Hall Christopher M | 期权行权／转换 (M) | Common Stock | 19,909 | USD 1.61 | USD 32,053 | SEC 申报 ↗ |
| 2026-05-12 | EASTHAM KARIN | 奖励／授予 (A) | Common Stock | 6,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-12 | WIDDER KENNETH J | 奖励／授予 (A) | Common Stock | 6,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-12 | Shoff Lonnie | 奖励／授予 (A) | Common Stock | 6,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-12 | MYERS WOODROW A JR | 奖励／授予 (A) | Common Stock | 6,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-12 | EASTHAM KARIN | 奖励／授予 (A) | Common Stock | 6,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-12 | Bloom Olivia Kyusuk | 奖励／授予 (A) | Common Stock | 6,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-12 | BOWMAN A BLAINE | 奖励／授予 (A) | Common Stock | 6,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-15 | Tachibana Aaron | 奖励／授予 (A) | Common Stock | 34,375 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | PSNL |
| CIK | 0001527753 |
| 行业 | Healthcare |
| 细分行业 | Diagnostics & Research Yahoo Finance |
| SEC SIC | 8071 Services-Medical Laboratories |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 278 transaction lines from 2020-01-07 to 2026-09-18 20 P purchase lines · 162 S sale lines · 96 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.